Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01011-6/abstract?dgcid=raven_jbs_etoc_feature_lancet